Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Healthtrust
Cipla
Queensland Health
QuintilesIMS
Harvard Business School

Generated: September 19, 2019

DrugPatentWatch Database Preview

AVAPRO Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which patents cover Avapro, and when can generic versions of Avapro launch?

Avapro is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AVAPRO is irbesartan. There are thirty-eight drug master file entries for this compound. Thirty suppliers are listed for this compound. Additional details are available on the irbesartan profile page.

Drug patent expirations by year for AVAPRO
Pharmacology for AVAPRO
Synonyms for AVAPRO
(-)-Styrene glycol; (R)-(-)-Phenylethylene glycol
[3H]irbesartan
1,3-Diazaspiro(4.4)non-1-en-4-one, 2-butyl-3-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-
1,3-Diazaspiro[4.4]non-1-en-4-one, 2-butyl-3-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-
138402-11-6
2-(n-butyl)-3-[[2'-(tetrazol-5-yl)biphenyl-4-yl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-({4-[2-(1H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one
2-Butyl-3-(p-(o-1H-tetrazol-5-ylphenyl)benzyl)-1,3-diazaspiro(4.4)non-1-en-4-one
2-butyl-3-[ p -( o -1 H -tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4,4]non-1-en-4-one
2-BUTYL-3-[[2'-(2H-TETRAZOL-5-YL)[1,1'-BIPHENYL]-4-YL]METHYL]-1,3-DIAZASPIRO[4.4]NON-1-EN-4-ONE
2-butyl-3-[[4-[2-(1H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-[2'-(1h-tetrazol-5-yl)-biphenyl-4-ylmethyl]-1,3-diaza-spiro[
2-butyl-3-[2'-(1h-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[
2-Butyl-3-[2'-(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]1,3-diaza-spiro[4.4]non-1-en-4-one
2-butyl-3-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)[1,1''-biphenyl]-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-butyl-3-{[2''-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl}-1,3-diazaspiro[4.4]non-1-en-4-one
2-n-butyl-3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-1,3-diazaspiro(4,4)non-1-en-4-one
2-n-butyl-3-<<2'-(1H-tetrazol-5-yl)biphenyl-4-yl>methyl>-1,3-diazaspiro<4.4>non-1-en-4-one;
3-((2'-(1H-Tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
3-((2'-(2H-tetrazol-5-yl)biphenyl-4-yl)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
402I116
4CA-0654
54246-EP2270011A1
54246-EP2295406A1
54246-EP2295422A2
54246-EP2298772A1
54246-EP2298776A1
54246-EP2298779A1
54246-EP2301923A1
54246-EP2301931A1
54246-EP2305219A1
54246-EP2308562A2
54246-EP2308839A1
8-butyl-7-[[4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
8-butyl-7-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]-7,9-diazaspiro[4.4]non-8-en-6-one
A807387
AB0013366
AB00639954_07
AB00639954_08
AB00639954-06
AB07472
AB1009632
ABP000523
AC-537
AC1L1GMK
AK-57149
AKOS005576396
AKOS015895353
AM90289
AN-15743
Aprovel
Avapro (TN)
BC207567
BCP02004
BCP9000792
BCPP000202
BDBM50042235
BIDD:GT0347
BMS 186295
BMS-186295
BR-57149
BRD-K60038276-001-02-5
BRD-K60038276-001-03-3
BSPBio_002687
C07469
C25H28N6O
CAS-138402-11-6
CCG-101012
CCG-39091
CHEBI:5959
CHEMBL1513
CPD000466306
CS-2140
D00523
DB01029
DSSTox_CID_3169
DSSTox_GSID_23169
DSSTox_RID_76900
DTXSID0023169
EBD8758
FT-0601598
GTPL589
GTPL6908
H931
HMS1922J05
HMS2051L08
HMS2093E16
HMS2232F23
HMS3370B06
HMS3393L08
HMS3715L04
HSDB 8215
HY-B0202
I06-0690
I0859
Irbesarran
irbesartan
Irbesartan ,(S)
Irbesartan (Avapro)
Irbesartan (JP17/USAN/INN)
Irbesartan [USAN:INN]
Irbesartan [USAN:USP:INN:BAN]
Irbesartan BMS
Irbesartan Krka
Irbesartan Winthrop
Irbesartan, >=98% (HPLC), powder
Irbesartan, European Pharmacopoeia (EP) Reference Standard
Irbesartan, Pharmaceutical Secondary Standard; Certified Reference Material
Irbesartan, United States Pharmacopeia (USP) Reference Standard
Irbesartan(Avapro)/
Irbetan
J0E2756Z7N
J10394
Jsp002315
Karvea
KB-52707
KBio2_002231
KBio2_004799
KBio2_007367
KBio3_001907
KBioGR_001603
KBioSS_002231
KS-00000ISW
KS-1151
L000319
Lrbesartan
LS-60064
MCULE-9617953373
MFCD00864464
MLS000759408
MLS001424099
MolPort-003-666-550
MolPort-006-167-687
NC00262
NCGC00095122-01
NCGC00095122-02
NCGC00095122-03
NCGC00095122-05
NSC-758696
NSC758696
Pharmakon1600-01504259
PubChem21382
Q-201249
S-1797
S1507
SAM001246548
SBI-0206769.P001
SC-08814
SCHEMBL4246
SMR000466306
SPBio_001889
Spectrum_001751
SPECTRUM1504259
Spectrum2_001675
Spectrum3_000994
Spectrum4_001122
Spectrum5_001288
SR 47436
SR-05000001997
SR-05000001997-1
SR-47436
ST24028252
STK645362
TL8000875
Tox21_111433
Tox21_111433_1
UNII-J0E2756Z7N
YOSHYTLCDANDAN-UHFFFAOYSA-N
ZINC3872931

US Patents and Regulatory Information for AVAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-001 Sep 30, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-003 Sep 30, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Expired US Patents for AVAPRO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-001 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-003 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-002 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-001 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AVAPRO irbesartan TABLET;ORAL 020757-003 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for AVAPRO
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 75 mg, 150 mg and 300 mg ➤ Subscribe ➤ Sign Up

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Fish and Richardson
AstraZeneca
Federal Trade Commission
Daiichi Sankyo
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.